

THRU ONLINE FILING

February 7, 2026

BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 023
Scrip Code – 524494

National Stock Exchange India Limited,
Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex, Bandra – (East).
Mumbai-400051.
Scrip Code : IPCALAB

Dear Sirs,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we had vide our letter dated 5th December, 2025, intimated to you about US FDA inspection of Company's Active Pharmaceutical Ingredients (API) manufacturing facility situated at Tarapur (Palghar-Maharashtra) from 1st December, 2025 to 5th December, 2025.

This manufacturing facility has now received Establishment Inspection Report classifying the manufacturing facility as "Voluntary Action Indicated (VAI) and that this facility is considered to be in a minimally acceptable state of compliance with regard to current good manufacturing practice (CGMP).

Thanking you

Yours faithfully
For Ipca Laboratories Limited

A. K. Jain
Managing Director
DIN 00012657

Ipca Laboratories Ltd.
www.ipca.com

125, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6210 5000 F: +91 22 6210 5005
Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6647 4444
E: ipca@ipca.com CIN: L24239MH1949PLC007837